(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Tumor Treating Fields therapy demonstrates increased overall survival in patients with unresectable pancreatic cancer. The ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

This discovery points to a new way to tackle pancreatic cancer. If scientists can find a way to block CD9 or stop the cancer ...

Pancreatic cancer has a poor prognosis accounting for a 5-year overall survival rate lower than 10%. This proportion could reach about one-third of patients ...

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...